Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company. The litigation revolves ...

Recent multi-gene studies of this generic complex indicated that the genus llyonectria is paraphyletic. The present study was therefore initiated to re-evaluate the generic status of llyonectria and ...

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year ...